Improvement of Diabetic Macular Edema in the Fellow Eye After Monocular Intravitreal Bevacizumab Injection

Hamidreza Torabi

Baqiyatallah University of Medical Sciences, Tehran, Iran

Abstract

Introduction: Because of bilateral involvement in many cases with diabetic macular edema, intravitreal bevacizumab injection perform in both eyes. There are some reports of therapeutic effects in the fellow eye after monocular injection of anti-vascular endothelial growth factor. In this study we describe a case of bilateral improvement of diabetic macular edema following unilateral intravitreal bevacizumab injection.

Case Presentation: We report a patient with bilateral non-proliferative diabetic retinopathy and diabetic macular edema. Central macular thickness was 398 µ in the right eye and 337 µ in the left eye. Two months after intravitreal injection of 1.25 mg bevacizumab in the right eye, significant improvement of diabetic macular edema was happened in both eyes including the left eye without intravitreal injection. Central macular thickness was 245 µ in the right eye and 250 µ in the left eye.

Conclusion: Unilateral injection of intravitreal bevacizumab may have therapeutic effects in the fellow untreated eye. Therefore; unilateral injection in bilateral cases may reduce the costs and complications of bilateral injection.

Keywords: Bevacizumab, Macular edema, Diabetic retinopathy, Optical coherence tomography

1. Introduction

Bevacizumab is a recombinant humanized monoclonal antibody directed against human vascular endothelial growth factor (VEGF). Recent studies have demonstrated the beneficial effects and safety of anti-VEGFs in the treatment of diabetic macular edema (DME). Bilateral injection of anti-VEGFs is usually performed, because DME frequently presents bilaterally. There are reports of therapeutic effects in the fellow eye after the monocular injection of anti-VEGFs, including decreased fluorescein leakage in the fellow eye after intravitreal injection of 1.25 mg of bevacizumab in patients with DME.

The current study describes an interesting case of significant improvement of DME in the contralateral eye after the monocular intravitreal injection of bevacizumab.

2. Case Presentation

A 54-year-old man with a history of diabetes mellitus type II presented with decreased vision in both eyes. The anterior segment was normal in a slit-lamp examination. Fundoscopy showed bilateral non-proliferative diabetic retinopathy with DME. Optical coherence tomography (OCT) was performed. The central macular thickness was 398 µ OD and 337 µ OS (Figures 1A & B).

Intravitreal injection of 1.25 mg/0.05 mL bevacizumab was performed in the right eye. Two months later the patient presented for examination, and OCT was done. Surprisingly, significant improvement of DME had occurred in both eyes, including the left eye that had not received intravitreal injection. Central macular thickness was 245 µ in the right eye and 250 µ in the left eye (Figures 2A & B). The patient was not referring for further follow up.

3. Discussion

Today, the potential effect of unilateral injection of anti-VEGFs in the fellow eye is controversial. In a prospective study, Gamulescu and Helbig showed no effects in the fellow eye of 26 eyes with bilateral neovascular age-related
macular degeneration treated with ranibizumab. Another study by Velez-Montoya et al showed that unilateral bevacizumab injection in 23 patients with bilateral DME had no effect on the fellow eye.

Several studies have demonstrated the potential effects of unilateral anti-VEGF injection in fellow eye; for example, Hanhart et al reported that unilateral bevacizumab injection in patients with bilateral DME is often associated with bilateral response. Zlatcavitch et al reported a patient with progression to macula-off tractional retinal detachment in a contralateral eye within 7 days after intravitreal injection of bevacizumab. Wu et al described a patient with macular edema due to branch retinal vein occlusion (BRVO) in the right eye and choroidal neovascularization in the left eye. They showed that intravitreal injection of bevacizumab in the right eye resulted in a reduction in macular edema in the left eye and vise versa.

Recent studies have revealed that the anti-VEGF concentration in the fellow eye increased after unilateral injection. The peak concentration of bevacizumab in the aqueous humor of the fellow eye after the unilateral injection of 1.25 mg bevacizumab occurred 7 days after injection; about 4 weeks after injection, peak concentration of bevacizumab occurred in the vitreous of the fellow eye.

In this study, we report a patient with bilateral DME in which significant improvement in macular edema was seen after the intravitreal injection of 1.25 mg of bevacizumab in the contralateral eye. Therefore, therapeutic effects of bevacizumab in the fellow eye are possible, and further research is required to document such fellow eye effects. Unilateral injection of anti-VEGFs for bilateral disease, if probable, can lead to a reduction of costs and complications.

4. Conclusion
The unilateral injection of intravitreal bevacizumab may have therapeutic effects in the fellow eye and reduce the costs and complications of bilateral injection in patients with bilateral disease.

Conflict of Interest Disclosures
The author declares that he has no conflicts of interest.

Ethical Approval
This study was approved by the Ethics Committee of the local hospital.

References